freephone 0800 862 0373
Sign in to view your quotes
Email address:
Password or PIN:

Forgotten your password? Reset it here.

Drug RoActemra successfully treats rheumatoid arthritis in clinical trials

Published on 08/06/2012

Clinical trials of a drug for rheumatoid arthritis prove four times more successful for patients than the most widely prescribed alternative.

Rheumatoid arthritis is an autoimmune disease. This is when your immune system, which usually fights infection, attacks the cells that line your joints, making them swollen, stiff and painful. Of those newly diagnosed, around half will be unable to work within 10 years.


A new drug for rheumatoid arthritis proved successful in clinical trials

Unfortunately, there is currently no cure for rheumatoid arthritis, so treatment is focused on controlling the progression of the disease and its symptoms.

The leading treatment for rheumatoid arthritis is methotrexate (MTX). However, about a third of patients cannot take it die to unbearable side effects like vomiting, hair loss and mouth ulcers. These patients move onto other drugs called anti-TNFs. The most common of these is adalimumab (Humira).

In the latest trial, scientists compared new anti-TNF drug tocilizumab, marketed as RoActemra, with Humira on 326 patients unable to tolerate MTX. They found that RoActemra was almost four times as likely to halt the progression of rheumatoid arthritis, and achieved a greater reduction in symptoms after six months.

Scientists presented their findings in Berlin at Eular- the annual meeting of the European Congress of Rheumatology. Professor John Isaacs, a rheumatology expert from the University of Newcastle, said: "These results are very important and exciting.

"For the tens of thousands of patients in the UK that can't take methotrexate, RoActemra will offer them an increased chance of remission, which is the ultimate goal of rheumatoid arthritis treatment."

"This study is the first time a treatment has gone 'head to head' with an anti-TNF in this setting, and to show a significant increase in patients achieving remission is very impressive."

At £9,500 per patient per year, RoActemra costs about the same as Humira. NICE has already approved RoActemra when combined with MTX, but the new results may lead to the drug being given to more patients on its own.

© ActiveQuote Ltd. 2012


Categories:  Medical
Drug RoActemra successfully treats rheumatoid arthritis in clinical trialsClinical trials of a drug for rheumatoid arthritis prove four times more successful for patients than the most widely prescribed alternati    tweet it on twittershare with your friends on Facebookshare with your friends on MySpaceBlog it on your LinkedIn profile
 

No.1 health insurance broker as rated by customers

Proactive, efficient, and offered me insurance I need. I would say half price I would end up paying if I did it by myself. Many thanks.

Review centre member

Excellent service. Explained everything in detail and really helped to find the right insurance best suited to my needs - which wasn't necessarily the most expensive. 

Review centre member

Good value and the advisor was very helpful and recommended the best policy for my grandson. I would definitely use this service again and recommend to others.

Review centre member

We were contacted in good time to make a knowledgable choice. We were given plenty of options with lots of information to enable us to make the right choice.

Review centre member

The service I received was excellent, the staff member was very efficient and knowledgable. She went out of her way to get the best policy for me.

Review centre member

Great service. I really appreciated the help provided by Active Quote to arrange health insurance. The agent was very informative and proactive. Many thanks!

Review centre member

I received excellent care and attention from the first phone call till the last. Friendly, efficient and patient.

Review centre member

Staff are very helpful, friendly and polite. They call back when they say they will and keep you up to date with progress. Pleasure to deal with.

Review centre member

Very polite and friendly, and gave detailed explanations of all aspects of the cover. Reassuring to know that if you do have a problem there is someone you can contact.

Review centre member

Friendly and efficient. Nothing was too much trouble even when i needed to make a small change, excellent service.

Review centre member
 
This site is operated by Insurance Broker ActiveQuote Ltd registered in England & Wales company number 6765845.
Authorised and Regulated by the Financial Conduct Authority (FCA). Firm reference number 501109 as detailed on the Financial Services Register. Please read our Key Facts document.
For information about your rights as a consumer visit Citizens Advice.

Our insurance comparison service is free and easy for you to use, but you are responsible for making sure all your information is entered correctly, and for choosing your insurer.

This site uses cookies in order to work correctly - these are not harmful and do not contain personal information. By using this site you consent to this. I understand  Tell me more

please wait ...